Business NewsPR NewsWire • R&D Productivity Measures Consistently Under-Scored and Under-Valued, EvaluatePharma Data Reveals

R&D Productivity Measures Consistently Under-Scored and Under-Valued, EvaluatePharma Data Reveals

R&D Productivity Measures Consistently Under-Scored and Under-Valued, EvaluatePharma Data Reveals

LONDON, March 14, 2011 /PRNewswire/ -- - Major Biologic Approvals Worth $4.5bn in 2015 Omitted From Most FDA Approval Counts Last Year - Provenge and Prevnar 13 Overlooked in Majority of 2010 Tallies - 65 new Biologics Have Largely Gone Uncounted in the Last 12 Years - Overall

View More : http://www.prnewswire.com/news-releases/rd-productivity-measures-consistently-under-scored-and-under-valued-evaluatephar...
Releted News by prnewswire
Cryo Workstation Breaks World Records
HL Technology Group 2010 Net Profit Jumps 75.1% to RMB155.0 Million
Cell Therapeutics Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers
R&D Productivity Measures Consistently Under-Scored and Under-Valued, EvaluatePharma Data Reveals
Apple or Google: Which Stock Will Perform Better?
Global Immune Technologies Executes Sales Agreement with French Distributor